

OFFICE OF THE SECRETARY OF STATE

SHEMIA FAGAN
SECRETARY OF STATE

CHERYL MYERS
DEPUTY SECRETARY OF STATE



ARCHIVES DIVISION

STEPHANIE CLARK
DIRECTOR

800 SUMMER STREET NE
SALEM, OR 97310
503-373-0701

NOTICE OF PROPOSED RULEMAKING
INCLUDING STATEMENT OF NEED & FISCAL IMPACT

CHAPTER 855
BOARD OF PHARMACY

FILED

10/21/2022 9:52 AM
ARCHIVES DIVISION
SECRETARY OF STATE

FILING CAPTION: Adds multiple new definitions to Division 006

LAST DAY AND TIME TO OFFER COMMENT TO AGENCY: 11/22/2022 4:30 PM

The Agency requests public comment on whether other options should be considered for achieving the rule's substantive goals while reducing negative economic impact of the rule on business.

CONTACT: Rachel Melvin
971-673-0001
pharmacy.rulemaking@bop.oregon.gov

800 NE Oregon St., Suite 150
Portland, OR 97232

Filed By:
Rachel Melvin
Rules Coordinator

HEARING(S)

Auxiliary aids for persons with disabilities are available upon advance request. Notify the contact listed above.

DATE: 11/22/2022

TIME: 9:30 AM

OFFICER: Rachel Melvin

ADDRESS: Oregon Board of Pharmacy
800 NE Oregon St., Suite 150
Portland, OR 97232

SPECIAL INSTRUCTIONS:

This hearing meeting will be held virtually via Microsoft Teams.

If you wish to present oral testimony during this hearing, sign up on our website at www.oregon.gov/pharmacy/pages/rulemaking-information or email your contact information to pharmacy.rulemaking@bop.oregon.gov to receive the link to join the virtual meeting. Please indicate which rule(s) you would like to comment on.

Alternatively, you may dial
503-446-4951
Phone Conference ID:
146 611 440#
for audio only.

You must submit written comments before 4:30PM on November 22, 2022. Email written comments to pharmacy.rulemaking@bop.oregon.gov.

NEED FOR THE RULE(S)

Proposed amendments to Division 006 will add definitions for "board approved school or college of pharmacy", amends clinical pharmacy agreement definition by adding appropriate statute references and "naturopathic physician". It also adds definitions for "Counseling", "Drug Regimen Review" (DRR), "Drug Utilization Review" (DUR), "Good Standing",

"Independent Practice of Pharmacy", "Intern", Pharmacist", "Pharmacy Area" and "Preceptor". Repeals definitions for "Oral Counseling", "Participation in drug selection and Drug Utilization Review" and "Responsibility for advising, when necessary or when regulated, of therapeutic values, content, hazards and use of drugs and devices. Repeals OAR 855-019-0110. Adds "board approved" and rule reference to OAR 855-031-0005.

DOCUMENTS RELIED UPON, AND WHERE THEY ARE AVAILABLE

None available.

STATEMENT IDENTIFYING HOW ADOPTION OF RULE(S) WILL AFFECT RACIAL EQUITY IN THIS STATE

Proposed rule amendments provide clarity for licensees, registrants. It is anticipated that these amendments will not impact any group of people differently than others.

FISCAL AND ECONOMIC IMPACT:

No fiscal impact is anticipated.

COST OF COMPLIANCE:

(1) Identify any state agencies, units of local government, and members of the public likely to be economically affected by the rule(s). (2) Effect on Small Businesses: (a) Estimate the number and type of small businesses subject to the rule(s); (b) Describe the expected reporting, recordkeeping and administrative activities and cost required to comply with the rule(s); (c) Estimate the cost of professional services, equipment supplies, labor and increased administration required to comply with the rule(s).

There are no known economic impacts to the agency, other state or local government, small businesses, or members of the public.

DESCRIBE HOW SMALL BUSINESSES WERE INVOLVED IN THE DEVELOPMENT OF THESE RULE(S):

Small businesses were not involved in the development of the proposed rule amendments.

WAS AN ADMINISTRATIVE RULE ADVISORY COMMITTEE CONSULTED? NO IF NOT, WHY NOT?

Board staff recommends adopting the proposed amendments for transparency and clarity for licensees and registrants.

RULES PROPOSED:

855-006-0005, 855-019-0110, 855-031-0005

AMEND: 855-006-0005

RULE SUMMARY: Proposed amendments include adding "board approved school or college of pharmacy", amends clinical pharmacy agreement definition by adding references to ORS 677.010 and 685.010 and adds "naturopathic physician". Adds definitions for "Counseling", "Drug Regimen Review" (DRR), "Drug Utilization Review" (DUR), "Good Standing", "Independent Practice of Pharmacy", "Intern", "Pharmacist", "Pharmacy Area" and "Preceptor". Repeals in the definition in 006-0005(33) related to participation in drug selection and DUR and to the definition of responsibility for advising in 006-0005(46). Repeals 855-019-0010. Amends 855-031-0005 by removing outdated language related to Interns and adds a reference to new definition in Division 006 related to "board approved". Proposed amendments will ensure clarity by informing licensees that these definitions apply across all Divisions in OAR 855.

CHANGES TO RULE:

855-006-0005
Definitions ¶

As used in OAR Chapter 855:¶

- (1) "Adulterated" has the same meaning as set forth in 21 USC 351 (v. 3/15/2022).¶
- (2) "Alarm system" means a device or series of devices, which emit or transmit an audible or remote visual or electronic alarm signal, which is intended to summon a response.¶
- (3) "Audiovisual communication system" means a continuously accessible, two-way audiovisual link that allows audiovisual communication in real-time and that prevents unauthorized disclosure of protected health information.¶
- (4) "Biological product" means, with respect to the prevention, treatment or cure of a disease or condition of human beings, a virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component, blood derivative, allergenic product, protein other than a chemically synthesized polypeptide, analogous products or arsphenamine or any other trivalent organic arsenic compound.¶
- (5) "Biosimilar" product means a biological product licensed by the United States Food and Drug Administration pursuant to 42 USC 262(k)(3)(A)(i) (03/15/2022).¶
- (6) "Board" means the Oregon Board of Pharmacy unless otherwise specified or required by the context.¶
- (7) "Board-approved school or college of pharmacy" means an ACPE accredited, accredited with probation, pre-candidate or candidate status (v. 6/2022) or a Canadian Council for Accreditation of Pharmacy Programs (CCAPP) accredited pharmacy program (v. 6/2022) with a curriculum taught in English;¶
- (8) "Certified health care interpreter" has the meaning given that term in ORS 413.550.¶
- (89) "Certified Oregon Pharmacy Technician" means a person licensed by the State Board of Pharmacy who assists the Pharmacist in the practice of pharmacy pursuant to rules of the board and has completed the specialized education program pursuant to OAR 855-025-0005. Persons used solely for clerical duties, such as recordkeeping, cashiering, bookkeeping and delivery of medications released by the Pharmacist are not considered Certified Oregon Pharmacy Technicians or Pharmacy Technicians.¶
- (910) "Clinical Pharmacy Agreement" means an agreement between a Pharmacist or pharmacy and a health care organization or a physician ~~that permits the Pharmacist to engage in the practice of clinical pharmacy for the benefit of the patients of the health care organization or physician.¶~~
- (10) ~~"Collaborative Drug Therapy Management" means as defined in ORS 677.010 or a naturopathic physician as defined in ORS 685.010 the participation by aat permits the Pharmacist in the management of drug therapy pursuant to a written protocol that includes information specific to the dosage, frequency, duration, and route of administration of the drug, authorized by a practitioner and initiated upon a prescription order for an individual patient and:¶~~
- (a) ~~Is agreed to by one Pharmacist and one practitioner; or¶¶~~
- (b) ~~Is agreed to by one or more Pharmacists at a single pharmacy registered by the board and one or more practitioners in a single organized medical group, such as a hospital medical staff, clinic, or group practice, including but not limited to organized medical groups using a pharmacy and therapeutics committee to engage in the practice of clinical pharmacy for the benefit of the patients of the health care organization, or physician or naturopathic physician.¶~~
- (11) "Compounding" means the preparation, mixing, assembling, packaging, or labeling of a drug or device:¶
 - (a) As the result of a practitioner's prescription drug order, or initiative based on the relationship between the practitioner, the Pharmacist and the patient, in the course of professional practice; or¶
 - (b) For the purpose of, or as an incident to, research, teaching, or chemical analysis and not for sale or dispensing; or¶
 - (c) The preparation of drugs or devices in anticipation of prescription drug orders based on routine, regularly observed prescribing patterns.¶
- (12) "Confidential Information" means any patient information obtained by a Pharmacist or pharmacy.¶
- (13) "Consulting Pharmacist" means a Pharmacist that provides a consulting service regarding a patient medication, therapy management, drug storage and management, security, education, or any other pharmaceutical service.¶
- (14) The "Container" is the device that holds the drug and that is or may be in direct contact with the drug.¶
- (15) "Counseling" or "Counsel" means an interactive communication between a Pharmacist and a patient or a patient's agent in which the Pharmacist provides the patient or patient's agent with advice regarding the safe and effective use of a drug or device.¶
- (16) "Custodian of pharmacy records" means a board licensee or registrant who is responsible for the maintenance, care or keeping of pharmacy records based on the services provided by the pharmacy, regardless of whether the records are in that person's actual physical custody and control.¶
- (167) "Dispensing" or "Dispense" means the preparation and delivery of a prescription drug pursuant to a lawful order of a practitioner in a suitable container appropriately labeled for subsequent administration to or use by a patient or other individual entitled to receive the prescription drug.¶

(178) "Drug Regimen Review" or "DRR" means the process conducted by a Pharmacist who is consulting for a long-term-care facility or other institution, either prior to dispensing or at a later time, with the goal of ensuring that optimal patient outcomes are achieved from the drug therapy.¶

(19) "Drug utilization review" or "DUR" means evaluation of a prescription to identify and resolve potential problems through the review of information provided to the Pharmacist by the patient, patient's agent, prescriber and the patient's record.¶

(20) "Entry system" enables control of access to a secured area.¶

(218) "Final verification" means after prescription information is entered into a pharmacy's electronic system and reviewed by a Pharmacist for accuracy, a physical verification that the drug and drug dosage, device or product selected from a pharmacy's inventory pursuant to the electronic system entry is the prescribed drug and drug dosage, device, or product.¶

(1922) "Good standing" means a license or registration that is not suspended, revoked, or otherwise restricted from the practice of pharmacy or subject to a current disciplinary order.¶

(23) "Health care interpreter" has the meaning given that term in ORS 413.550.¶

(204) "Health care interpreter registry" means the registry described in ORS 413.558 that is administered by the Oregon Health Authority.¶

(245) "Independent Practice of Pharmacy" means the provision of clinical pharmacy services not related to the dispensing, distribution and delivery of drugs or devices. ¶

(26) "Individual with limited English proficiency" means a person who, by reason of place of birth or culture, communicates in a language other than English and does not communicate in English with adequate ability to communicate effectively with a health care provider.¶

(227) "Interchangeable" means, in reference to a biological product, that the United States Food and Drug Administration has determined that a biosimilar product meets the safety standards set forth in 42 USC 262(k)(4) (03/15/2022).¶

(238) "Intern" means a person who is enrolled in or has completed a course of study at a school or college of pharmacy approved by the board and who is licensed with the board as an Intern.¶

(29) "Interpretation and evaluation of prescription orders" means the review of the order for therapeutic and legal correctness. Therapeutic review includes identification of the prescription drug ordered, its applicability and its relationship to the other known medications used by the patient and determination of whether or not the dose and time interval of administration are within accepted limits of safety. The legal review for correctness of the prescription order includes a determination that the order is valid and has not been altered, is not a forgery, is prescribed for a legitimate medical purpose, contains all information required by federal and state law, and is within the practitioner's scope of practice.¶

(2430) "Labeling" means the process of preparing and affixing of a label to any drug container exclusive, however, of the labeling by a manufacturer, packer or distributor of a non-prescription drug or commercially packaged legend drug or device.¶

(2531) "Misbranded" has the same definition as set forth in 21 USC 352 (v. 03/15/2022).¶

(326) "Monitoring of therapeutic response or adverse effect of drug therapy" means the follow up of the therapeutic or adverse effect of medication upon a patient, including direct consultation with the patient or his agent and review of patient records, as to result and side effect, and the analysis of possible interactions with other medications that may be in the medication regimen of the patient. This section shall not be construed to prohibit monitoring by practitioners or their agents.¶

(2733) "Medication Therapy Management (MTM)" means a distinct service or group of services that is intended to optimize therapeutic outcomes for individual patients. Medication Therapy Management services are independent of, but can occur in conjunction with, the provision of a medication product.¶

(2834) "Nationally Certified Exam" means an exam that is approved by the board which demonstrates successful completion of a Specialized Education Program. The exam must be reliable, psychometrically sound, legally defensible, and valid.¶

(2935) "Non-legend drug" means a drug which does not require dispensing by prescription and which is not restricted to use by practitioners only.¶

(306) "Offering or performing of those acts, services, operations or transactions necessary in the conduct, operation, management and control of pharmacy" means, among other things:¶

(a) The creation and retention of accurate and complete patient records;¶

(b) Assuming authority and responsibility for product selection of drugs and devices;¶

(c) Developing and maintaining a safe practice setting for the Pharmacist, for pharmacy staff and for the general public;¶

(d) Maintaining confidentiality of patient information.¶

(317) "Official compendium" means the official United States Pharmacopeia <USP>, official National Formulary <NF> (USP NF 2022, Issue 1), official Homeopathic Pharmacopoeia of the United States <HPUS> (v. 2022), or any

supplement to any of these.¶

(328) "Oral Counseling" means an oral communication process between a Pharmacist and a patient or a patient's agent in which the Pharmacist obtains information from the patient (or agent) and the patient's pharmacy records, assesses that information, and provides the patient (or agent) with professional advice regarding the safe and effective use of the prescription drug for the purpose of assuring therapeutic appropriateness.¶

(33) Participation in Drug Selection and Drug Utilization Review:¶

(a) "Participation in drug selection" means the consultation with the practitioner in the selection of the best possible drug for a particular patient. Pharmaceutical Care means the responsible provision of drug therapy for the purpose of achieving definite outcomes that improve a patient's quality of life. These outcomes include:¶

(a) Cure of a disease;¶

(b) Elimination or reduction of a patient's symptomatology;¶

(c) Arrest or slowing of a disease process; or¶

(b) "Drug utilization review" means evaluating prescription drug order in light of the information currently provided to the Pharmacist by the patient or the patient's agent and in light of the information contained in the patient's record for the purpose of promoting therapeutic appropriateness by identifying potential problems and consulting with the prescriber, when appropriate. Problems subject to identification during drug utilization review include, but are not limited to:¶

(A) Over-utilization or under-utilization;¶

(B) Therapeutic duplication;¶

(C) Drug-disease contraindications;¶

(D) Drug-drug interactions;¶

(E) Incorrect drug dosage;¶

(F) Incorrect duration of treatment;¶

(G) Drug-allergy interactions; and¶

(H) Clinical drug abuse or misuse. Prevention of a disease or symptomatology.¶

(39) "Pharmacist" means an individual licensed by this state to engage in the practice of pharmacy or to engage in the practice of clinical pharmacy.¶

(340) "Pharmaceutical Care Area" means the responsible provision of drug therapy for the purpose of achieving definite outcomes that improve a patient's quality of life. These outcomes include:¶

(a) Cure of a disease;¶

(b) Elimination or reduction of a patient's symptomatology;¶

(c) Arrest or slowing of a disease process; or¶

(d) Prevention of a disease or symptomatology or devices, records, and equipment used to access pharmacy records are located.¶

(3541) "Pharmacy Technician" means a person licensed by the State Board of Pharmacy who assists the Pharmacist in the practice of pharmacy pursuant to rules of the board but has not completed the specialized education program pursuant to OAR 855-025-0012.¶

(3642) "Practice of clinical pharmacy" means:¶

(a) The health science discipline in which, in conjunction with the patient's other practitioners, a Pharmacist provides patient care to optimize medication therapy and to promote disease prevention and the patient's health and wellness;¶

(b) The provision of patient care services, including but not limited to post-diagnostic disease state management services; and¶

(c) The practice of pharmacy by a Pharmacist pursuant to a clinical pharmacy agreement.¶

(437) "Practice of pharmacy" is as defined in ORS 689.005.¶

(3844) "Preceptor" means a Pharmacist or a person licensed by the board to supervise the internship training of a licensed intern.¶

(45) "Prescription drug" or "legend drug" is as defined in ORS 689.005 and:¶

(a) Required by federal law, prior to being dispensed or delivered, to be labeled with "Rx only"; or¶

(b) Required by any applicable federal or state law or regulation to be dispensed on prescription only or is restricted to use by practitioners only.¶

(3946) "Prescription released by the Pharmacist" means, a prescription which has been reviewed by the Pharmacist that does not require further Pharmacist intervention such as reconstitution or counseling.¶

(407) "Prohibited conduct" means conduct by a licensee that:¶

(a) Constitutes a criminal act against a patient or client; or¶

(b) Constitutes a criminal act that creates a risk of harm to a patient or client.¶

(418) "Proper and safe storage of drugs and devices and maintenance of proper records therefore" means housing drugs and devices under conditions and circumstances that:¶

(a) Assure retention of their purity and potency;¶

- (b) Avoid confusion due to similarity of appearance, packaging, labeling or for any other reason;¶¶
- (c) Assure security and minimize the risk of their loss through accident or theft;¶¶
- (d) Accurately account for and record their receipt, retention, dispensing, distribution or destruction;¶¶
- (e) Protect the health, safety and welfare of the Pharmacist, pharmacy staff and the general public from harmful exposure to hazardous substances.¶¶
- (429) "Quality Assurance Plan" is a written set of procedures to ensure that a pharmacy has a planned and systematic process for the monitoring and evaluation of the quality and appropriateness of pharmacy services and for identifying and resolving problems.¶¶
- (4350) "Reasonable professional judgment" means an objectively reasonable and impartial belief, opinion or conclusion held with confidence, and founded on appropriate professional knowledge, skills, abilities, qualifications, and competencies, after careful review, analysis and consideration of the relevant subject matter and all relevant facts and circumstances that were then known by, or reasonably available to, the person or party holding such belief, opinion, or conclusion.¶¶
- (4451) "Reference biological product" means the biological product licensed pursuant to 42 USC 262(a) (03/15/2022) against which a biological product is evaluated in an application submitted to the United States Food and Drug Administration for licensure of a biological product as a biosimilar product or for determination that a biosimilar product is interchangeable.¶¶
- (452) "Repackage" means the act of taking a drug from the container in which it was distributed by the manufacturer and placing it into a different container without further manipulation of the drug.¶¶
- ~~(46) "Responsibility for advising, when necessary or when regulated, of therapeutic values, content, hazards and use of drugs and devices" means advice directly to the patient, either verbally or in writing as required by these rules or federal regulation, of the possible therapeutic response to the medication, the names of the chemicals in the medication, the possible side effects of major importance, and the methods of use or administration of a medication.¶¶~~
- (4753) "Specialized Education Program" means;¶¶
 - (a) A program providing education for persons desiring licensure as Certified Oregon Pharmacy Technicians or Pharmacy Technicians that is approved by the board and offered by an accredited college or university that grants a two-year degree upon successful completion of the program; or¶¶
 - (b) A structured program approved by the board and designed to educate Certified Oregon Pharmacy Technicians or Pharmacy Technicians in one or more specific issues of patient health and safety that is offered by:¶¶
 - (A) An organization recognized by the board as representing Pharmacists, Certified Oregon Pharmacy Technicians or Pharmacy Technicians;¶¶
 - (B) An employer recognized by the board as representing Pharmacists, Certified Oregon Pharmacy Technicians or Pharmacy Technicians; or¶¶
 - (C) A trade association recognized by the board as representing pharmacies.¶¶
- (548) "Still image capture" means a specific image captured electronically from a video or other image capture device.¶¶
- (4955) "Store and forward" means a video or still image record which is saved electronically for future review.¶¶
- (506) "Supervision by a Pharmacist" means being stationed within the same work area, except as authorized under OAR 855-041-3200 through OAR 855-041-3250, as the Intern, Certified Oregon Pharmacy Technician or Pharmacy Technician being supervised, coupled with the ability to control and be responsible for the Intern, Certified Oregon Pharmacy Technician or Pharmacy Technician's action.¶¶
- (517) "Surveillance system" means a system of video cameras, monitors, recorders, and other equipment used for surveillance.¶¶
- (528) "Therapeutic substitution" means the act of dispensing a drug product with a different chemical structure for the drug product prescribed under circumstances where the prescriber has not given clear and conscious direction for substitution of the particular drug for the one which may later be ordered.¶¶
- (539) "Verification" means the confirmation by the Pharmacist of the correctness, exactness, accuracy and completeness of the acts, tasks, or functions performed by an Intern, a Certified Oregon Pharmacy Technician, or a Pharmacy Technician.

Statutory/Other Authority: ORS 689.205, 2022 HB 4034

Statutes/Other Implemented: ORS 689.151, ORS 689.155, 2022 HB 4034

REPEAL: 855-019-0110

RULE SUMMARY: Repeals 855-019-0010. Definitions related to "Clinical Pharmacy Agreement", "Counseling", "Drug Regimen Review (DRR)", Drug Utilization Review (DUR), "Medication Therapy Management (MTM)", "Practice of Clinical Pharmacy", and "Practice of Pharmacy" are located in OAR 855-006-0005

Proposed repeal is necessary to ensure clarity by informing licensees that these definitions apply across all Divisions in OAR 855.

CHANGES TO RULE:

~~855-019-0110~~

~~Definitions~~

~~In this Division of Rules:~~

- ~~(1) "Clinical Pharmacy Agreement" means an agreement between a pharmacist or pharmacy and a health care organization or a physician that permits the pharmacist to engage in the practice of clinical pharmacy for the benefit of the patients of the health care organization or physician.~~
- ~~(2) "Collaborative Drug Therapy Management (CDTM)" has the same meaning as defined in OAR 855-006-0005.~~
- ~~(3) "Counseling" means an oral or other appropriate communication process between a pharmacist and a patient or a patient's agent in which the pharmacist obtains information from the patient or patient's agent, and, where appropriate, the patient's pharmacy records, assesses that information and provides the patient or patient's agent with professional advice regarding the safe and effective use of the drug or device for the purpose of assuring therapeutic appropriateness.~~
- ~~(4) "Drug Regimen Review (DRR)" means the process conducted by a pharmacist who is consulting for a long-term care facility or other institution, either prior to dispensing or at a later time, with the goal of ensuring that optimal patient outcomes are achieved from the drug therapy.~~
- ~~(5) "Drug Utilization Review (DUR)" has the same meaning as defined in OAR 855-006-0005.~~
- ~~(6) "Medication Therapy Management (MTM)" means a distinct service or group of services that is intended to optimize therapeutic outcomes for individual patients. Medication Therapy Management services are independent of, but can occur in conjunction with, the provision of a medication product.~~
- ~~(7) "Practice of Clinical Pharmacy" means:~~
 - ~~(a) The health science discipline in which, in conjunction with the patient's other practitioners, a pharmacist provides patient care to optimize medication therapy and to promote disease prevention and the patient's health and wellness;~~
 - ~~(b) The provision of patient care services, including but not limited to post-diagnostic disease state management services; and~~
 - ~~(c) The practice of pharmacy by a pharmacist pursuant to a clinical pharmacy agreement.~~
- ~~(8) "Practice of Pharmacy" is as defined in ORS 689.005.~~

~~Statutory/Other Authority: ORS 689.205~~

~~Statutes/Other Implemented: ORS 689.005, 689.151, 689.155~~

AMEND: 855-031-0005

RULE SUMMARY: Amends 855-031-0005 by removing outdated language related to Interns and adds a reference to new definition in Division 006 related to "board approved". Proposed amendments will ensure clarity by informing licensees that these definitions apply across all Divisions in OAR 855.

CHANGES TO RULE:

855-031-0005

Definitions ¶¶

~~(1) An "intern" means any person who:¶¶~~

~~(a) Is enrolled in a course of study and is in good academic standing at a school or college of pharmacy that is approved by the Oregon Board of Pharmacy; or¶¶~~

~~(b) Is a graduate of a school or college of pharmacy that is approved by the board; or¶¶~~

~~(c) Is a foreign pharmacy graduate and holds a certificate from the Foreign Pharmacy Graduate Equivalency Committee (FPGEC); and¶¶~~

~~(d) Is licensed with the board as an intern.¶¶~~

~~(2) A "preceptor" means a pharmacist or a person licensed by the board to supervise the internship training of an intern.¶¶~~

~~(3) "Internship" means a professional experiential program or work experience.¶¶~~

~~(a) "Traditional Pharmacy-practice Internship (TPI)" means experience toward achieving competency in the practice of pharmacy for which no academic credit is granted to the intern.¶¶~~

~~(b) "School-based Rotational Internship (SRI)" means experience toward achieving competency in the practice of pharmacy in programs developed and administered by a school of pharmacy.¶¶~~

~~(c) "Other Internship" means experience toward achieving competency in the practice of pharmacy, other than in an internship as defined in (a) or (b), in a program approved by a school of pharmacy or the board.¶¶~~

~~(42) "School of pharmacy": In this division of rules, "school of pharmacy" means a Board-approved school or college of pharmacy that is approved by the board as defined in OAR 855-006-0005.~~

Statutory/Other Authority: ORS 689.151, ORS 689.205

Statutes/Other Implemented: ORS 689.255